Adnexal and clinical effects of myoinositol and lipoic acid in PCOs patients

Abstract

Background: Polycistic ovary syndrome (PCOs) is one of the most common endocrine and metabolic disorders in premenopausal women. Our team aimed to know an eventual significant effect of the therapy based on an Alfa Lipoic Acid (ALA)/Myoinositol (Myo) combined drug on adnexal parameters as assessed by ultrasound and follow up clinical analysis. Methods: The following represents the results of a prospective trial considering data from thirty italian nulliparous women considered for the study, chosen from an initial group of fifty-eight women, compared to data taken from a healthy women group paired by age and nulliparous status. The mean age was 30.1 years old. Patients underwent a Myoinositol (400 mg) plus ALA (800 mg) regimen twice a day in a continued fashion in a twenty four months period. Ultrasound examinations were coincident with the fifth day of menstrual period and were set as follows: Time 0 (first evaluation), Time 12 (after twelve months) and finally Time 24 (after 24 months). Results: Comparisons were performed between Time 0 and Time 12 paired data, No significant ultrasound parameters differences were found between paired patients regarding: endometrial width, number of follicles and ovarian volume at the time of the trial. Regarding clinical symptoms, menstrual pelvic pain significantly decreased after a mean time of about four months and menstrual cycle tended to be regular in 12 from 30 patients after eight months under therapy. Parameters dealing with ultrasound color Doppler velocimetry status were studied considering other twelve months and will be described in a further report considering only ultrasound parameters. Conclusions: Considering the preliminary results of this study, we may hypothesize that Inositol may block the vascular effects of hyperadrogenism, and that the ALA in addition may play a role regarding anti oxidant and anti inflammatory pathways